Cancer | Biomarker study | Significance | Reference |
OA | Loss of chromosome 1p and 19q | Sensitive to chemotherapy and better prognosis | |
NSCLC | ERCC1/MDR1 SNP DNA mehtylation and repair Kappa B Deletion of chromosome 11p15 | Associated with sensitivity to platinum Predict chemosensitivity Predict chemosensitivity Resistance to gemcitabine | |
Brest | HER-2 BRCA 1 mutation P53 mutation TNBC | Poorer prognosis Conflict results of chemosensitivity Drug resistance Sensitive to chemotherapy and biological therapy | |
Stomach | Oncogene, antioncogenes, DNA repair, receptors, | Diagnosis and predict chemosensitivity | |
Skin | DNA microarray | Diagnosis and predict chemosensitivity | |
PETs | Loss of heterogosity, alterations of oncogenesantioncogenes, growth factors and receptors | Prognostic significance Targetable gene and protein | |
Head and neck | EGFR P53 gene and protein | Prognosis Predict clinical outcome | |
AML | Microarray combine with flow cytometry | Predict chemosensitivity, diagnostic and pharmacokinetic study | |
OVA | CA-125 change | Predict the treatment outcome | |
OA TNBC PETs | Oligodendroglioma Triple negative breast cancer Pancreactic endocrine tumors |